Recruiting Phase 2 NCT04322890

Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

Trial Parameters

Condition Non Small Cell Lung Cancer

Sponsor Hunan Province Tumor Hospital

Study Type INTERVENTIONAL

Phase Phase 2

Enrollment 6,000

Sex ALL

Min Age 18 Years

Max Age N/A

Start Date 2020-04-16

Completion 2026-12-24

All Conditions

Non Small Cell Lung Cancer EGFR Gene Mutation ALK Gene Mutation ROS1 Gene Mutation MET Gene Mutation

Interventions

OsimertinibAlectinib 150 MGCrizotinib 250 MG

Brief Summary

The purpose of this study is to assess the Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation.

Eligibility Criteria

Inclusion Criteria: 1. Understand the requirements and contents of the clinical trial, and provide a signed and dated informed consent form. 2. Age ≥ 18 years. 3. Histologically or cytologically confirmed, Stage IV NSCLC. 4. Oncogenic mutations confirmed by an accredited local laboratory, including EGFR, ALK, ROS1 etc. 5. ECOG 0-1. 6. Predicted survival ≥ 12 weeks. 7. Adequate bone marrow hematopoiesis and organ function 8. Presence of measurable lesions according to RECIST 1.1. Exclusion Criteria: The patient did not match from the Inclusion Criteria.

Related Trials

NCT06476093

SRT Combined With Anlotinib for the Treatment of Brain Metastases From Non-small Cell Lung Cancer

View Trial →

NCT06272864

BostonGene and Exigent Genomic INsight Study

View Trial →

NCT06809764

Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m N

View Trial →

VIEW ON CLINICALTRIALS.GOV ↗ MORE NON SMALL CELL LUNG CANCER TRIALS